Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27740481 | 0.98 | TDP1 (0.52) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL2122837 | 0.96 | TDP1 (0.50) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL5801967 | 0.96 | TDP1 (0.50) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL27648828 | 0.89 | PDE4A (0.48) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL27844168 | 0.83 | TDP1 (0.55) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL19951539 | 0.83 | TDP1 (0.55) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL2337822 | 0.83 | TDP1 (0.55) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL2341187 | 0.83 | TDP1 (0.55) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| SCHEMBL28448089 | 0.83 | TDP1 (0.55) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| Water SCHEMBL27605931 | 0.82 | TDP1 (0.48) | TDP1PDE4ALMNAL3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017029353-A1 | TREATMENT OF BEHAVIORS IN DEMENTIA PATIENTS | TRANSITION THERAPEUTICS IRELAND LIMITED (IE) | 2017-02-23 | — | — | WO | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2656839-A1 | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases | Waratah Pharmaceuticals, Inc. (CA) | 2013-10-30 | — | — | EP | disclosed |
| EP-2148667-B1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC (CA) | 2013-05-22 | — | — | EP | disclosed |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE | 2011-05-05 | — | — | US | disclosed |
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | MCLAURIN JOANNE | 2010-12-30 | — | — | US | disclosed |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE | 2010-06-10 | — | — | US | disclosed |
| EP-2148667-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | Waratah Pharmaceuticals, Inc. (CA) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008124940-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124929-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124930-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124931-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | SNCA, PARK7, PMP22 | TDP1 1908/4885PDE4A 3538/4885LMNA 2167/4885 |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | CDR2, HYPK, HTT | TDP1 1100/4885PDE4A 2952/4885LMNA 2646/4885 |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | APP, IAPP, TTR | TDP1 2467/4885PDE4A 3769/4885LMNA 2340/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | TDP1 2475/4885PDE4A 3853/4885LMNA 2073/4885 |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SOD3, SMN1; SMN2 | TDP1 2051/4885PDE4A 4746/4885LMNA 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.